» Articles » PMID: 38535612

Fungemia by -A Narrative Review

Overview
Journal Pathogens
Date 2024 Mar 27
PMID 38535612
Authors
Affiliations
Soon will be listed here.
Abstract

has been previously classified as , , and and was recently reclassified in the genus after phylogenetic analysis of its genetic sequence. An increasing number of reports of human infections by have emerged, suggesting that this microorganism is an emerging pathogen. The present review aimed to provide data on the epidemiology, antifungal resistance, clinical characteristics, treatment, and outcomes of fungemia by by extracting all the available information from published original reports in the literature. PubMed/Medline, Cochrane Library, and Scopus databases were searched for eligible articles reporting data on patients with this disease. In total, 36 studies involving 170 patients were included. The age of patients with fungemia by ranged from 0 to 89 years; the mean age was 22.8 years, the median age was 2.2 years, with more than 37 patients being less than one month old, and 54% (88 out of 163 patients) were male. Regarding patients' history, 70.4% had a central venous catheter use (CVC), 28.7% were on total parenteral nutrition (TPN), 97% of neonates were hospitalized in the neonatal ICU (NICU), and 39.4% of the rest of the patients were hospitalized in the intensive care unit (ICU). Previous antimicrobial use was noted in 65.9% of patients. The most common identification method was the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 34.1%, VITEK and VITEK 2 in 20.6%, and ID32 C in 15.3%. had minimal antifungal resistance to fluconazole, echinocandins, and amphotericin B, the most commonly used antifungals for treatment. Fever and sepsis were the most common clinical presentation noted in 95.8% and 86%, respectively. Overall mortality was 20% and was slightly higher in patients older than one year. Due to the rarity of this disease, future multicenter studies should be performed to adequately characterize patients' characteristics, treatment, and outcomes, which will increase our understanding and allow drawing safer conclusions regarding optimal management.

Citing Articles

Bloodstream Infection in Oncologic Patient: First Report in Poland.

Sulik-Tyszka B, Malyszko J, Peczula A, Jarzynka S J Fungi (Basel). 2025; 11(2).

PMID: 39997389 PMC: 11856704. DOI: 10.3390/jof11020095.


Short Tandem Repeat Genotyping of Medically Important Fungi: A Comprehensive Review of a Powerful Tool with Extensive Future Potential.

Spruijtenburg B, Meis J, Verweij P, de Groot T, Meijer E Mycopathologia. 2024; 189(5):72.

PMID: 39096450 PMC: 11297828. DOI: 10.1007/s11046-024-00877-8.

References
1.
Mohamed A, Lu X, Mounmin F . Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. Can J Gastroenterol Hepatol. 2019; 2019:3585136. PMC: 6854261. DOI: 10.1155/2019/3585136. View

2.
Snayd M, Dias F, Ryan R, Clout D, Banach D . Misidentification of Candida auris by RapID Yeast Plus, a Commercial, Biochemical Enzyme-Based Manual Rapid Identification System. J Clin Microbiol. 2018; 56(5). PMC: 5925697. DOI: 10.1128/JCM.00080-18. View

3.
Denning D, Kneale M, Sobel J, Rautemaa-Richardson R . Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018; 18(11):e339-e347. DOI: 10.1016/S1473-3099(18)30103-8. View

4.
Ioannou P, Papakitsou I . Kodamaea ohmeri infections in humans: A systematic review. Mycoses. 2020; 63(7):636-643. DOI: 10.1111/myc.13094. View

5.
Klein A, Tortora G, Malowitz R, Greene W . Hansenula anomala: a new fungal pathogen. Two case reports and a review of the literature. Arch Intern Med. 1988; 148(5):1210-3. DOI: 10.1001/archinte.148.5.1210. View